肝复康对肝纤维化大鼠肝组织整合素α5β1/FAK信号通路的调节作用*

doi:10.3969/j.issn.1672-5069.2012.02.008

实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (2): 104-107.doi: 10.3969/j.issn.1672-5069.2012.02.008

肝复康对肝纤维化大鼠肝组织整合素α5β1/FAK信号通路的调节作用^*

张坤, 姜妙娜, 张彩华, 贾玉杰

116044 辽宁省大连市大连医科大学病理生理学教研室

收稿日期:2011-12-08 出版日期:2012-04-10 发布日期:2017-03-07
通讯作者: 贾玉杰,E-mail:pathophy@163.com
作者简介:张坤女,32岁,讲师。主要从事消化系统疾病病理生理学研究。原工作单位为包头医学院。E-mail:kunkunlove0508@163.com
基金资助:
辽宁省自然科学基金资助（编号：201102055）

Effect of Gan-fu-kang compound on hepatic expression of integrinα5β1/FAK signal pathway in carbon tetrachloride-induced liver fibrosis in rats

Zhang Kun, Jiang Miaona, Zhang Caihua, et al.

Department of Pathophysiology,Dalian Medical University,Dalian 116044, Liaoning Province,China

Received:2011-12-08 Online:2012-04-10 Published:2017-03-07

摘要/Abstract

摘要： 目的研究整合素α5β1/FAK信号通路在肝纤维化中的作用以及中药肝复康对此通路的影响。方法将SD大鼠随机分为正常对照组、模型组、肝复康大剂量、中剂量和小剂量治疗组,皮下注射10%CCl4制备肝纤维化模型,自第9周起,给予肝复康灌胃治疗至第20周。采用免疫组化法检测大鼠肝组织整合素α5和整合素β1的表达情况;采用RT-PCR法检测FAK mRNA水平。结果模型组大鼠肝组织整合素α5表达水平（0.50±0.01）比正常对照组（0.23±0.13）明显增高（P<0.01）,而肝复康治疗后（大、中、小剂量治疗组分别为0.35±0.03、0.33±0.01、0.38±0.02）比模型组明显降低（P<0.01）;模型组大鼠肝组织整合素β1表达水平（0.44±0.02）比正常对照组（0.27±0.01）明显增高（P<0.01）,肝复康治疗后（大、中、小剂量治疗组分别为0.37±0.01、0.34±0.01、0.39±0.01）表达水平较模型组明显降低（P<0.01）;模型组动物FAK mRNA水平（0.73±0.01）比正常对照组（0.11±0.02）明显增高（P<0.01）,而肝复康治疗后（大、中、小剂量治疗组分别为0.33±0.03、0.28±0.01、0.18±0.01）比模型组明显降低（P<0.01）。结论整合素α5β1/FAK信号通路的激活在肝纤维化中发挥重要作用,肝复康治疗肝纤维化作用的机制可能与抑制整合素α5β1/FAK通路的信号转导有关。

关键词: 肝纤维化, 肝复康, 整合素α5β1/FAK信号通路, 大鼠

Abstract: Objective To study the effect of traditional Chinese medicine Gan-fu-kang（GFK）on hepatic expression of integrinα5β1/ focal adhesion kinase（FAK） in carbon tetrachloride-induced liver fibrosis in rats. Methods SD rats were randomly divided into control,model,low,middle and high dose of GFK treatment groups. Liver fibrosis models of rats were made by subcutaneously injecting with 10%CCl₄. GFK was orally given daily with GFK from week 9 to 20. The expression of integrinα5 and integrinβ1 protein and FAK mRNA were detected by immunohistochemical and RT-PCR techniques,respectively. Results The level of integrinα5 expression in model group（0.50±0.01）was obviously increased as compared with that in control group（0.23±0.13,P<0.01）,and it was obviously downregulated in high,middle and low dose of GFK treatment groups respectively （0.35±0.03,0.33±0.01,0.38±0.02）as compared with model group（P<0.01）; Similarly,the level of integrinβ1 expression in model group（0.44±0.02） was obviously increased as compared with that in control group（0.27±0.01,P<0.01）,and it was decreased in high,middle and low dose of GFK treatment groups respectively（0.37±0.01,0.34±0.01,0.39±0.01） as compared with model group（P<0.01）;At the same time,FAK mRNA level in model group（0.73±0.01）was obviously higher than that in control group（0.11±0.02,P<0.01）,while it was lower in high,middle and low dose of GFK treatment groups respectively（0.33±0.03,0.28±0.01,0.18±0.01）than that in model group（P<0.01）.Conclusion The activated integrinα5β1/FAK signal pathway may play an important role in liver fibrosis,and the therapeutic mechanisms of Gan-fu-kang on hepatic fibrosis may be related to the inhibition of this signal pathway.

Key words: Liver fibrosis, Gan-fu-kang, Integrinα5β1/FAK signal pathway, Rats

张坤, 姜妙娜, 张彩华, 贾玉杰. 肝复康对肝纤维化大鼠肝组织整合素α5β1/FAK信号通路的调节作用^*[J]. 实用肝脏病杂志, 2012, 15(2): 104-107.

Zhang Kun, Jiang Miaona, Zhang Caihua, et al.. Effect of Gan-fu-kang compound on hepatic expression of integrinα5β1/FAK signal pathway in carbon tetrachloride-induced liver fibrosis in rats[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(2): 104-107.

参考文献

[1] Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol,2008,214（2）:199-210.
[2] Zhou X,Zhang Y,Zhang J,et al. Expression of fibronectin receptor,integrin alpha 5 beta 1 of hepatic stellate cells in rat liver fibrosis. Chin Med J （Engl）,2000,113（3）:272-276.
[3] Sengbusch V,Gassmann P,Katja M,et al. Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within Liver sinusoids. AJP,2005,166（2）:585-596.
[4] 车颖,徐婷婷,姜妙娜,等. 肝复康胶囊对实验性肝纤维化大鼠肝细胞的保护作用. 中药材,2004,27（6）:428-429.
[5] Xu TT,Jiang MN,Li C. Effect of Chinese traditional compound,Gan-fu-kang,on CCl 4 induced liver fibrosis in rats and its probable molecular mechanisms. Hepatol Res,2007,37:221-229.
[6] Lou JL,Jiang MN,Li C,et al. Herb medicine Gan-fu-kang attenuates liver injury in a rat fibrotic model. J Ethnopharmacol,2010,128:131-138.
[7] 张彩华,姜妙娜,袁丽君,等. 肝复康对HSC-T6细胞Wnt信号转导通路调节作用的观察. 实用肝脏病杂志,2011,14（4）:253-256.
[8] Milliano MT,Luxon BA.Initial signaling of the fibronection receptor（alph5beta1 integrin） in hepatic stellate cells is independent of lyrosine phosphorylation. Hepatology,2003,39（1）:32-37.
[9] Huveneers S,Truong H,Fassler F,et al. Binding of soluble fibronectin to integrin α5β1 link to focal adhesion redistribution and contractile shape. J Cell Sci,2008,121（15）:2452-2462.
[10] 宋正己,王吉耀. 整合素与肝星状细胞活化. 肝脏,2007,12（6）:505-507.
[11] Huang G,Brigstok DR. Integrin expression and function in the response of primary culture hepatic stellate cells to connective tissue growth factor（CCN2）. J Cell Mol Med,2011,15（5）:1087-1095.
[12] 安君艳,张晓岚,姚冬梅,等. FAK基因的RNA干扰对肝星状细胞生物活性的影响. 基础医学与临床,2009,29（10）:1044-1049.
[13] Cox BD,Natarajan M,Stettner MR,et al. New concepts regarding focal adhension kinase promotion of cell migration and proliferation. J Cell Biochem,2006,99（1）:35-52.
[14] 耿建章,甄真,陈翠英,等. 整合素α5β1及黏着斑激酶在肝纤维化中的作用. 疑难病杂志,2009,8（6）:344-346.
[15] Zhou XH,Zhang YE,Zhang JS,et al. Expression of fibronectin recepter,integrinα5β1 of hepatic stellate cells in rat liver fibrosis. Chin Med J,2000,113（3）:272-276.
[16] 刘成海,宜红萍,陶艳艳,等. 基于FN/整合素信号途径探讨扶正化瘀方抑制肝星状细胞活化的作用机制.上海中医药杂志,2008,42（1）:3-7.

肝复康对肝纤维化大鼠肝组织整合素α5β1/FAK信号通路的调节作用^*

Effect of Gan-fu-kang compound on hepatic expression of integrinα5β1/FAK signal pathway in carbon tetrachloride-induced liver fibrosis in rats

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2]	徐飞, 李伟荣. 黄芪甲苷对CCL₄所致肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 808-811.
[3]	高磊, 曹蕾, 王瑞芳, 冯丹丹, 薛娟. 人脐带间充质干细胞移植对酒精性肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 812-815.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[7]	林秋香, 王雪雯, 黄祖雄, 潘晨. 灯盏花素对肝脏缺血再灌注损伤大鼠肝脏和肠黏膜屏障功能的保护作用*[J]. 实用肝脏病杂志, 2019, 22(5): 636-639.
[8]	石小龙, 杜睿, 秦革萍, 薛华燕, 张宏鑫. 七氟醚对脓毒症大鼠肝损伤的保护作用及其作用机制研究*[J]. 实用肝脏病杂志, 2019, 22(5): 640-643.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	王艳, 苏峰, 李园园, 李舒. 蜂毒溶血肽改善非酒精性脂肪肝大鼠肝组织脂肪沉积作用及其机制研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 474-477.
[11]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[12]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[13]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[14]	周丽云, 李校天, 李丽, 杨俊超. 1,25（OH）₂D₃通过调节miR-146a水平抑制大鼠肝纤维化的体内和体外观察[J]. 实用肝脏病杂志, 2019, 22(3): 333-336.
[15]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.